BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SCTC21C readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SCTC21C\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07538154-3146@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SCTC21C: Phase 1/2 readout est. (NCT07538154)
DESCRIPTION:SCTC21C\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: A C
 linica Study of SCTC21C in Participants With Systemic Lupus Erythematosus\
 nEstimated primary completion: April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sctc21c#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07538154
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06774664-3146@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SCTC21C: Phase 1/2 readout est. (NCT06774664)
DESCRIPTION:SCTC21C\, phase 1/2\, IgA Nephropathy.\nStudy: A Clinical Study
  of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sctc21c#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06774664
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3146@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SCTC21C: Phase 3 readout est. (NCT07297329)
DESCRIPTION:SCTC21C\, phase 3\, Multiple Myeloma.\nStudy: A Study to Evalua
 te the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, Len
 alidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myel
 oma Not Eligible for Transplant\nEstimated primary completion: December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sctc21c#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07297329
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388602-3146@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SCTC21C: Phase 3 readout est. (NCT07388602)
DESCRIPTION:SCTC21C\, phase 3\, AL Amyloidosis.\nStudy: A Study to Evaluate
  the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, Cyclo
 phosphamide\, and Dexamethasone in Patients With Newly Diagnosed Systemic 
 Light-Chain Amyloidosis (NDSLCA)\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sctc21c#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07388602
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
